Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

This publication has 41 references indexed in Scilit:

• Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1
  Schizophrenia Research, 2008
• Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women
  JAMA, 2007
• Change in Framingham Risk Score in Patients With Schizophrenia
  The Primary Care Companion For CNS Disorders, 2006
• Extent and Management of Cardiovascular Risk Factors in Patients With Type 2 Diabetes and Serious Mental Illness
  Journal of Nervous & Mental Disease, 2006
• A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
  Schizophrenia Research, 2005
• The metabolic syndrome and schizophrenia: A review
  International Review of Psychiatry, 2005
• A Study of Quetiapine: Efficacy and Tolerability in Psychotic Adolescents
  Journal of Child and Adolescent Psychopharmacology, 2001
• The Apparent Effects of Ziprasidone on Plasma Lipids and Glucose
  The Journal of Clinical Psychiatry, 2001
• Excess mortality of schizophrenia
  The British Journal of Psychiatry, 1997
• The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)
  Archives of internal medicine (1960), 1993